E11
Conditions
Interventions
Group 1: Patients with T2DM were prescribed SGLT2 inhibitors and/or GLP-1RA inhibitors for 3-6 months and underwent genetical testing for related polymorphisms and clinical testing for treatment respo
Sponsors
Faculty of Medicine, University of Ljubljana
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Criteria 1: previous diagnosis of type 2 diabetes mellitus Criteria 2: met the inclusion criteria for treatment with newer antihyperglycaemic drugs (SGLT2 inhibitors and/or GLP-1RA inhibitors)
Exclusion criteria
Exclusion criteria: Criteria 1: other types of diabetes mellitus Criteria 2: patients with significant cognitive impairment or psychiatric disorder Criteria 3: patients abusing alcohol or other drugs Criteria 4: patients with cancer or a history of cancer in the last 5 years)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycated haemoglobin (HbA1c), body weight, and blood pressure, before starting treatment with SGLT2 and/or GLP-1RA and after 3-6 months of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Genotype distribution for two GLP1R polymorphisms (rs6923761 and rs10305420) and one SLC5A2 polymorphism (rs9934336), using competitive allele-specific polymerase chain reaction (KASP) | — |
Countries
Slovenia
Contacts
Public ContactGašper Tonin
Faculty of Medicine, University of Ljubljana
Outcome results
None listed